Founded by Steven Damon, Micron Biomedical, Inc. is on a mission to improve health through innovation. The Atlanta-based clinical-stage biopharmaceutical company recently raised an impressive $17 million in Series A funding from J2 Ventures. Micron's proprietary applicator-free, dissolving, microneedle patch technology is designed to achieve better health outcomes through enhanced therapeutic effects, simplified logistics, and improved patient compliance. Micron's pharmaceutical products are based on its microneedle patch technology, designed to provide enhanced protective (vaccine) and therapeutic (drugs) effects, superior patient compliance, and simplified administration, distribution, and storage logistics. 

The benefits of Micron's microneedle patch technology stem from its proprietary design and manufacturing, which allow for skin-based targeting and delivery of actives, painless administration, customizable delivery profile based on indication, ease of use, thermostability allowing reduction or elimination of the cold chain for transportation and storage, simplified logistics, and no sharps waste. Micron's technology is poised to revolutionize the pharmaceutical industry, making it easier, more efficient, and pain-free to administer vaccines and drugs, while improving patient outcomes.